Adductor Canal Block in Outpatient Clinic for Pain Control After Knee Arthroplasty (ACB)

Adductor Canal Block in Outpatient Clinic

Single-shot Adductor Canal Block in the outpatient clinic is safe, significantly decreased pain and analgesic consumption and may enhance the rehabilitation program

Study Overview

• Status: Recruiting
• Conditions: Acute Pain; Total Knee Arthroplasty
• Intervention / Treatment: Drug: Analgesics, etoricoxibe; Procedure: adductor canal block in outpatient clinic

Detailed Description

The ACB in the outpatient clinic is safe and can minimize postoperative pain. The primary goal of this research was to see how ACB affected the Visual Analog Score (VAS) pain score during the rehabilitation as opposed to controls. The secondary goal was to determine how much analgesic (etoricoxibe) was consumed on a daily basis.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: sholahuddin rhatomy, Dr; Phone Number: +6281808720707; Email: sholahuddin.rhatomy@ugm.ac.id

Study Locations

• Indonesia
  • Yogyakarta
    • Sleman, Yogyakarta, Indonesia, 55281
      • Recruiting
      • Sholahuddin Rhatomy
      • Contact: sholahuddin rhatomy, Dr; Phone Number: +6281808720707; Email: sholahuddin.rhatomy@ugm.ac.id

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Indonesian or Javanese-speaking adults
• After perfomed total knee replacement
• American Society of Anesthesiologists physical status I-III
• body mass index (BMI) of 18-40 kg/m2

Exclusion Criteria:

• Declined to complete the study
• Unable to cooperate
• had an allergic reaction to any of the drugs
• abusing alcohol or drugs

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: pain management post total knee arthroplasty with analgetic oral; Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day.	Drug: Analgesics, etoricoxibe; anaelgetic oral intake; Other Names: etoricoxibe
Active Comparator: pain management post total knee arthroplasty with adductor canal block; On postoperative day 14 (POD 14), the ACB was performed for ACB group	Procedure: adductor canal block in outpatient clinic; perform adductor canal block in outpatient clinic for patient post total knee arthroplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual analog pain score (VAS)	A VAS scale was used to assess pain severity, with 0 indicating no pain and 10 indicating extreme pain	one month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
analgesic oral intake (etoricoxibe)	determine how much analgesic (etoricoxibe) was consumed on a daily basis.	one month

Collaborators and Investigators

• Sponsor: Gadjah Mada University
• Investigators: Principal Investigator: sholahuddin rhatomy, dr, Gadjah Mada University

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2020
• Primary Completion (Anticipated): June 1, 2021
• Study Completion (Anticipated): June 1, 2021

Study Registration Dates

• First Submitted: April 30, 2021
• First Submitted That Met QC Criteria: May 6, 2021
• First Posted (Actual): May 12, 2021

Study Record Updates

• Last Update Posted (Actual): May 12, 2021
• Last Update Submitted That Met QC Criteria: May 6, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Acute Pain; Physiological Effects of Drugs; Peripheral Nervous System Agents; Sensory System Agents; Analgesics
• Other Study ID Numbers: ACB OUTPATIENT CLINIC

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No